Immune Thrombocytopenia Associated with Efalizumab Therapy for Psoriasis
Authors: Theodore E. Warkentin, Paul Kwon
Journal: Annals of Internal Medicine (2005)

Letters15 November 2005Immune Thrombocytopenia Associated with Efalizumab Therapy for PsoriasisTheodore E. Warkentin, MD and Paul Kwon, MDTheodore E. Warkentin, MDFrom Hamilton Health Sciences, Hamilton, Ontario L8L 2X2, Canada and Genentech, South San Francisco, CA 94080. and Paul Kwon, MDFrom Hamilton Health Sciences, Hamilton, Ontario L8L 2X2, Canada and Genentech, South San Francisco, CA 94080.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-143-10-200511150-00028 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Background: Efalizumab is a recombinant humanized anti-CD11a monoclonal IgG1 antibody. Efalizumab recognizes the α-subunit of leukocyte function-associated antigen type 1, thereby blocking interaction between the antigen and intercellular adhesion molecules and associated signaling and T-cell migration (1). The agent is licensed for the treatment of moderate to severe plaque psoriasis (2).Objective: To describe the frequency, clinical features, and response to treatment of putative immune-mediated thrombocytopenia during efalizumab treatment.Methods: During the efalizumab clinical development program, 2762 patients were treated with the drug. We reviewed the case files of all patients with thrombocytopenia (classified by investigators as ...References1. Lebwohl M, Tyring SK, Hamilton TK, Toth D, Glazer S, Tawfik NH, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med. 2003;349:2004-13. [PMID: 14627785] CrossrefMedlineGoogle Scholar2. Efalizumab (Raptiva) for treatment of psoriasis. Med Lett Drugs Ther. 2003;45:97-8. [PMID: 14657802] MedlineGoogle Scholar3. George JN, Raskob GE, Shah SR, Rizvi MA, Hamilton SA, Osborne S, et al. Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Intern Med. 1998;129:886-90. [PMID: 9867731] LinkGoogle Scholar4. Neylon AJ, Saunders PWG, Howard MR, Proctor SJ, Taylor PRA. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients. Br J Haematol. 2003;122:966-74. [PMID: 12956768] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Hamilton Health Sciences, Hamilton, Ontario L8L 2X2, Canada and Genentech, South San Francisco, CA 94080.Disclosures: Employment: P. Kwon (Genentech); Consultancies: T.E. Warkentin (Genentech); Stock ownership: P. Kwon (Genentech). PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByPathophysiology and Diagnosis of Drug-Induced Immune ThrombocytopeniaDrug-induced thrombocytopenia: mechanisms and relevance in preclinical safety assessmentDrug-Induced ThrombocytopeniaDrug-Induced Thrombocytopenia: Pathogenesis, Diagnosis and ManagementEfalizumabUnexpected Hematologic Effects of Biotherapeutics in Nonclinical Species and in HumansDrug-Induced ThrombocytopeniaDrug-induced platelet disordersEfalizumabAdverse Drug Reactions Affecting Blood CellsEfalizumab-induced thrombocytopenia: report of relapse after re-administrationThrombocytopenia and Other Hot TopicsDrug-induced immune thrombocytopenia: pathogenesis, diagnosis, and managementThrombocytopenia associated with the use of anti–tumor necrosis factor–α agents for psoriasisLong-term data in the treatment of psoriasisDelayed autoimmune hemolytic anemia in efalizumab-treated psoriasisPancytopénie au cours d'un traitement par efalizumabEfalizumab-induced immune thrombocytopenia during retreatmentEfalizumab: ¿un tratamiento seguro para una enfermedad crónica?Drugs that act on the immune system: cytokines and monoclonal antibodiesFrom the Medical Board of the National Psoriasis Foundation: Monitoring and vaccinations in patients treated with biologics for psoriasisEfalizumab-associated thrombocytopeniaEfalizumabCurrent advancements in the treatment of psoriasis: Immunobiologic agentsBiologic Therapies for Inflammatory Disease 15 November 2005Volume 143, Issue 10Page: 761-763KeywordsClinical trialsCorticosteroid therapyDrug administrationDrug therapyDrugsIdiopathic thrombocytopenic purpuraPathogenesisPatientsPlateletsPsoriasis ePublished: 15 November 2005 Issue Published: 15 November 2005 CopyrightCopyright © 2005 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...